Lundbeck Presents New Data on Migraine-Related Cognitive Symptoms After VYEPTI® Treatment

Real-world study shows improvements in patient-reported cognitive issues like brain fog and difficulty concentrating after starting VYEPTI

Apr. 20, 2026 at 7:36am

Got story updates? Submit your updates here. ›

An extreme close-up macro X-ray photograph revealing the intricate internal structure of a human brain, glowing with ghostly translucent lines against a dark background, conceptually representing the cognitive challenges of migraine.A revealing X-ray view of the human brain highlights the complex neurological underpinnings of migraine-related cognitive symptoms.Deerfield Today

Lundbeck presented new data from the INFUSE study at the American Academy of Neurology 2026 Annual Meeting, highlighting real-world improvements in migraine-related cognitive symptoms among patients who started treatment with VYEPTI® (eptinezumab-jjmr). The study found that over 50% of participants reported improvements in issues like brain fog, decision-making difficulties, and trouble with reading comprehension just 6 months after beginning VYEPTI.

Why it matters

Migraine is a complex neurological disease that can significantly impact quality of life, and cognitive symptoms like brain fog are commonly reported by patients but have been understudied. These real-world data provide valuable insights into how preventive treatments like VYEPTI may help address the broader burden of migraine beyond just headache frequency.

The details

The INFUSE study is a 12-month observational study examining the real-world effectiveness of VYEPTI in adults with migraine who had previously failed at least one anti-CGRP preventive treatment. The 6-month interim analysis focused on patient-reported cognitive symptoms, finding that issues like difficulty making decisions, reading comprehension problems, and brain fog were considered moderately to extremely bothersome by 60-82% of participants at baseline. After starting VYEPTI, over 50% of these high-impact migraine patients reported improvements in these cognitive symptoms.

  • The INFUSE study is ongoing, with data collected at baseline, Day 7, and Months 3, 6, 9 and 12.

The players

VYEPTI® (eptinezumab-jjmr)

A humanized monoclonal antibody that binds to and blocks the calcitonin gene-related peptide (CGRP) ligand, indicated for the preventive treatment of migraine in adults.

Dr. Amaal Starling

Neurologist at Mayo Clinic and INFUSE study author.

Lundbeck

A global biopharmaceutical company focusing exclusively on brain health and the developer of VYEPTI.

Got photos? Submit your photos here. ›

What they’re saying

“'Migraine is a highly individualized neurological disease characterized by fluctuating symptoms, disability, and quality-of-life impairment. My patients often describe 'brain fog' associated with migraine as profoundly disruptive, hindering their ability to perform at work, engage with family, or simply enjoy daily life. The INFUSE study findings are meaningful as patients report improvements in cognitive symptoms associated with migraine after starting VYEPTI. These data further support more comprehensive goals with patients who have high disease burden despite prior anti-CGRP preventive treatment to better address their needs and improve outcomes.'”

— Dr. Amaal Starling, Neurologist, Mayo Clinic

“'These real-world, patient-reported INFUSE data give greater insight into the management of the holistic burden of migraine – including highly prevalent cognitive symptoms – to better support optimal treatment decisions. We're excited to share new data that may help redefine expectations for preventive migraine treatment and reinforce our commitment to raising the standard of migraine care.'”

— Damian Fiore, Vice President, Lundbeck US Medical Affairs Neurology

What’s next

The INFUSE study is ongoing, with data collection continuing through 12 months to further evaluate the real-world effectiveness of VYEPTI in this patient population.

The takeaway

These INFUSE study findings highlight the significant impact of migraine-related cognitive symptoms on patients' daily lives and the potential for preventive treatments like VYEPTI to provide meaningful improvements in this underappreciated aspect of the migraine burden.